Efficacy and Safety of Oral SERDs and Other Endocrine Therapies in ER+/HER2- Metastatic Breast Cancer

Experts explore the efficacy and safety profiles of elacestrant, an oral Selective Estrogen Receptor Degrader (SERD), and other options for endocrine therapy. The panelists also discuss clinical trial insights, progression-free survival rates, and tolerability, highlighting outcomes and advantages in metastatic breast cancer treatment.

Related Keywords

Rena Callahan ,Gregory Vidal ,William Gradishar ,Mabel Mardones ,Peer Exchange ,Oral Serd ,Mbc ,Metastatic Breast Cancer ,Iserd ,Therapeutic Advances ,Panel Discussion ,Her Positive ,Her2 Negative ,Selective Estrogen Receptor Degrader ,Endocrine Therapy ,Targeted Therapy ,Treatment Developments ,Medical Oncology ,Oncologist ,Breast Oncology ,Safety Profile ,Clinical Trial ,Treatment Comparison ,Elacestrant ,Fulvestrant ,Oncology ,Esr1 Mutation ,